Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

Published: Jun-2013 | Format: PDF | GBI Research | Code: MRS - 1273

GBI Research, a leading business intelligence provider, has released its latest research report “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth” The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. 

The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. Despite recent patent expirations, including that of Advair Diskus (salmeterol/fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as that observed in other indications. 

This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition. Although the COPD market is characterized by low diagnosis rates, campaigns to increase awareness of the disease in both patients and physicians has resulted in steadily rising diagnosis of COPD. Therefore, this has also contributed to market growth throughout the forecast period.

Scope

  • A disease introduction, which defines the disease, including symptoms, diagnosis and treatment.
  • An analysis of the COPD marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, displayed as a heat map.
  • A detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analysed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action.
  • An in-depth forecasting model for the COPD market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies. This takes into account worst and best case scenarios for market uptake, costs and patent expirations.
  • Strategic consolidations within the COPD indication are analyzed, which includes co-development and licensing agreements.
  • An overview of the drivers and barriers for the COPD market is also included.


Reasons to Buy

  • Primarily, the report will allow clients to gain a strong understanding of the COPD indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also allow you to:
  • Understand the COPD pipeline and the factors which indicate that it is becoming more innovative as well as the key pipeline molecules that look set to have a big impact upon the COPD market.
  • Observe detailed profiles for the promising pipeline products and gain insights into how they are likely to compete in the market, and what their main competitors will be.
  • Follow the trends in COPD clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for COPD therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
  • Observe the potential growth patterns expected for the COPD market over the forecast period, and identify which countries are expected to contribute most to this growth.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.7.1 Treatment Algorithm
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Product Profile
3.1.1 Spiriva – Boehringer Ingelheim Pharmaceuticals, Pfizer Inc.
3.1.2 Advair Diskus – GlaxoSmithKline
3.1.3 Symbicort – AstraZeneca (Co-promotion with Astellas Pharma Inc)
3.1.4 Combivent– Boehringer Ingelheim
3.1.5 Foradil – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Arcapta/Onbrez Breezhaler – Novartis
3.1.7 Daliresp – Nycomed
3.1.8 Seebri Breezhaler – Novartis
3.1.9 Striverdi Respimat – Boehringer Ingelheim
3.1.10 Relvar/Breo – GlaxoSmithKline/Theravance
3.1.11 Heat Map – Marketed Products Overview

4 COPD Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.4 Promising Pipeline Molecules
4.4.1 Umeclidinium Bromide – GlaxoSmithKline
4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline/Theravance
4.4.3 Vilanterol Trifenatate – GlaxoSmithKline/Theravance
4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim
4.4.5 TD-4208 – Theravance
4.4.6 QVA-149 – Novartis
4.4.7 Andolast (CR 2039) – Rottapharm | Madaus
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 United States
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the COPD Market
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Co-development Deals
6.1.1 Galapagos Enters into Strategic Alliance with Roche
6.1.2 Five Prime Therapeutics Enters into Co-development Agreement with GlaxoSmithKline
6.1.3 Forest Labs Enters into Co-development Agreement with Nycomed
6.2 Major Licensing Deals
6.2.1 Orexo Enters into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma
6.2.3 Evotec Enters into Licensing Agreement with Zhejiang Conba Pharma for EVT 401
6.2.4 Halozyme Therapeutics Enters into Licensing Agreement with Intrexon

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Pre-clinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.1.8 Market Forecasts to 2019
7.1.9 The United States
7.1.10 The UK
7.1.11 France
7.1.12 Germany
7.1.13 Italy
7.1.14 Spain
7.1.15 Japan
7.2 Market Definition
7.3 Abbreviations
7.4 References
7.4.1 References for Pipeline Heat Map
7.4.2 References for Marketed Products Heat Map
7.5 Methodology
7.6 Coverage
7.7 Secondary Research
7.8 Therapeutic Landscape
7.9 Epidemiology-Based Forecasting
7.10 Market Size by Geography
7.11 Geographical Landscape
7.12 Pipeline Analysis
7.13 Competitive Landscape
7.13.1 Expert Panel Validation
7.14 Contact Us
7.15 Disclaimer



List of Tables

Table 1: COPD Market, Introduction, Disease Severity, 2012
Table 2: COPD Market, Introduction, Treatment Algorithm, 2012
Table 3: COPD Market, Global, Pipeline, Discovery, 2013
Table 4: COPD Market, Global, Pipeline, Pre-clinical, 2013
Table 5: COPD Market, Global, Pipeline, Phase I, 2013
Table 6: COPD Market, Global, Pipeline, Phase II, 2013
Table 7: COPD Market, Global, Pipeline, Phase III, 2013
Table 8: COPD Market, Global, Pipeline, Filed, 2013
Table 9: COPD Market, Global, Pipeline, Undisclosed, 2013
Table 10: COPD, Global, Market Forecast, 2012–2019
Table 11: COPD, US, Market Forecast, 2012–2019
Table 12: COPD, UK, Market Forecast, 2012–2019
Table 13: COPD, France, Market Forecast, 2012–2019
Table 14: COPD, Germany, Market Forecast, 2012–2019
Table 15: COPD, Italy, Market Forecast, 2012–2019
Table 16: COPD, Spain, Market Forecast, 2012–2019
Table 17: COPD, Japan, Market Forecast, 2012–2019


List of Figures


Figure 1: COPD Market, Global, Marketed Products, Heat Map, 2012
Figure 2: COPD Market, Global, Pipeline, 2012
Figure 3: COPD Market, Global, Pipeline by Mechanism of Action, 2012
Figure 4: COPD Market, Global, Clinical Trials, Failure Rate, 2012
Figure 5: COPD Market, Global, Clinical Trials, Failure Rates by
Figure 6: COPD Market, Global, Pipeline, Failure Rates by Mechanism of Action, Heat Map, 2012
Figure 7: COPD Market, Global, Pipeline, Clinical Trial Duration, 2012
Figure 8: COPD Market, Global, Pipeline, Clinical Trial Duration by Mechanism, 2012
Figure 9: COPD Market, Global, Pipeline, Clinical Trial Size, 2012
Figure 10: COPD Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action, 2012
Figure 11: COPD Market, Global, Pipeline, Number of Clinical Trials per Drug, 2012
Figure 12: COPD Market, Global, Pipeline, Efficacy Heat Map, 2012
Figure 13: COPD Market, Global, Pipeline, Safety Heat Map, 2012
Figure 14: COPD Market, Global, Marketed Products, Heat Map, 2012
Figure 15: COPD Market, Global, Pipeline, Competitor Grid, 2012
Figure 16: COPD Market, Global, Treatment Patterns, 2012–2019
Figure 17: COPD Market, Global, Market Size ($m) 2012–2019
Figure 18: COPD Market, the US, Treatment Usage Patterns, Annual Cost of Treatment ($), 2012–2019
Figure 19: COPD Market, US, Market Size ($m), 2012–2019
Figure 20: COPD Market, Top Five EU Countries, Treatment Usage Patterns, 2012–2019
Figure 21: COPD Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 22: COPD Market, Top Five EU Countries, Market Size ($m), 2012–2019
Figure 23: COPD Market, Japan, Treatment Usage Patterns, Annual Cost of Treatment ($), 2012–2019
Figure 24: COPD Market, Japan, Market Size ($m), 2012–2019
Figure 25: COPD Market, Global, Co-development Deals, 2006–2012
Figure 26: COPD Market, Global, Number and Aggregate Value of Co-development Deals by Year, 2006–2013
Figure 27: COPD Market, Global, Licensing Deals, 2006–2012
Figure 28: COPD Market, Global, Number and Aggregate Value of Licensing Deals by Year, 2006–2012
Figure 29: COPD Market, Global, Licensing Deals, 2006–2012
Figure 30: COPD Market, Global, Licensing Deals by Phase and Molecule Type and Aggregate Deal Value, 2006–2012
Figure 31: COPD Market, Global, Licensing Deals by Mechanism of Action, 2006–2012
Figure 32: COPD Market, Global, GBI Research Market Sizing Model

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3500 View Pricing